Second-line liposomal irinotecan combo for pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new liposomal form of irinotecan in combination with other drugs as a second or later treatment for people with advanced pancreatic cancer that continued to grow after prior irinotecan therapy. It aims to see if this new combination can help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with advanced or metastatic pancreatic cancer that has gotten worse after treatment with irinotecan
- You have had no more than 3 different treatment plans for your cancer so far
- You are between 18 and 75 years old
- You are still active enough to do most of your daily activities on your own
- Your tumor(s) can be seen on a scan and measured
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two chemotherapy drugs (irinotecan liposome and capecitabine) for people with pancreatic cancer that has spread or cannot be removed by surgery and has gotten worse after initial treatment. The goal is to see if this combination can help slow the disease.
This study looks at how well a specific type of chemotherapy called irinotecan hydrochloride liposome works in people with pancreatic cancer. Researchers want to understand its effects in real-world settings, which may help doctors choose the best treatment for patients.
This trial tests a combination of three chemotherapy medicines (liposomal irinotecan, oxaliplatin, and tegafur) given after surgery to remove pancreatic cancer. The goal is to see if this treatment helps prevent the cancer from coming back.
This trial tests a combination of three chemotherapy drugs (irinotecan liposome, albumin-bound paclitaxel, and gemcitabine) as a first treatment for people with pancreatic cancer that has not spread to the brain. It aims to see if this combination works better than standard treatments.
This study looks at how well a treatment called liposomal irinotecan works for people with advanced pancreatic cancer that has spread. You may qualify if you have already tried a chemotherapy drug called gemcitabine and it stopped working.
This trial tests a new form of chemotherapy (irinotecan liposome) combined with two other chemo drugs, compared to a standard treatment, for people with metastatic pancreatic cancer who haven't had chemo yet.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.